Kilgore, Henry R. http://orcid.org/0000-0003-4851-9656
Mikhael, Peter G. http://orcid.org/0000-0002-6030-1636
Overholt, Kalon J. http://orcid.org/0000-0001-9127-9112
Boija, Ann
Hannett, Nancy M.
Van Dongen, Catherine http://orcid.org/0000-0003-2291-0948
Lee, Tong Ihn http://orcid.org/0000-0003-1847-0898
Chang, Young-Tae http://orcid.org/0000-0002-1927-3688
Barzilay, Regina
Young, Richard A. http://orcid.org/0000-0001-8855-8647
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (GM144283, CA155258)
National Science Foundation (PHY2044895, 1745302)
Damon Runyon Cancer Research Foundation (2458-22, 2458-22)
Article History
Received: 1 October 2022
Accepted: 31 August 2023
First Online: 28 September 2023
Change Date: 25 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41589-023-01491-3
Competing interests
: R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics, Dewpoint Therapeutics and Paratus Sciences, and has consulting or advisory roles at Precede Biosciences and Novo Nordisk. R.B. has consulting or advisory roles at Dewpoint Therapeutics, J&J, Amgen, Outcomes4Me, Immunai and Firmenich. H.R.K. is a consultant of Dewpoint Therapeutics. The remaining authors declare no competing interests.